Role of losartan in diabetic nephropathy

ABSTRACT

Based on World Health Organization statistics, the worldwide prevalence of diabetes is expected to increased from an estimated 155 million in the year 2000 to 300 million in 2025. Diabetic nephropathy is an important cause of morbidity and mortality and is now among the most common causes of end stage renal failure [ESRF] in the developed countries. Renin angiotensin system has been implicated in the pathophysiology of diabetic nephropathy and associated complications due to its specific effects on intra-glomerular blood flow, resistance and general effects. In this clinical trial we have used antitypertensive agent i.e., Losartan [AT-1 receptor blocker] and found it to be effective both in delaying the development of renal damage secondary to diabetes and avoidance of other major complications associated to diabetic nephropathy